## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.14 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($184.09)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. What Charles River Laboratories International (CRL)'s SEC Clearance and Analyst Upgrades Mean For Shareholders**
- Source: Simply Wall Street | 20251217T010805 | Bullish | Relevance: 100%
- Charles River Laboratories International (CRL) recently received SEC clearance and analyst upgrades, easing regulatory concerns and reinforcing its role in drug development. While these developments reduce regulatory overhang, the company still faces challenges with converting backlog to revenue, managing cancellations, and competitive pricing pressures. Investors should also consider the long-term risk of increasing adoption of non-animal testing methods on CRL's core business.

**2. Charles River Laboratories stock hits 52-week high at 200.51 USD**
- Source: Investing.com | 20251215T145604 | Bullish | Relevance: 100%
- Charles River Laboratories (CRL) stock has reached a new 52-week high of $200.51, reflecting a 1.56% increase over the past year and a 29.16% return over the last six months. This surge is underpinned by strong investor confidence, analyst expectations of profitability for the current year with a forecasted EPS of $10.34, and strategic share buybacks by management. Recent developments include multiple analyst upgrades and a concluded SEC investigation without enforcement action, contributing to its positive trajectory.

**3. JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating**
- Source: marketscreener.com | 20251215T140303 | Somewhat-Bullish | Relevance: 100%
- JPMorgan has adjusted its price target for Charles River Laboratories International (NYSE: CRL) to $190, an increase from the previous $165, while maintaining a Neutral rating on the stock. This update reflects the firm's revised outlook for the company, following other analyst activities for CRL. The article also provides recent news headlines and stock performance data for Charles River Laboratories International.

**4. Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High After Analyst Upgrade**
- Source: MarketBeat | 20251215T153005 | Bullish | Relevance: 100%
- Charles River Laboratories International (NYSE:CRL) achieved a new 52-week high after Bank of America upgraded its rating from neutral to buy, setting a $225 price target. The stock hit $202 and last traded around $198, following a previous close of $193.03. Analysts have a "Moderate Buy" consensus rating for CRL, with a target price of $192.29, and institutional investors hold a significant 98.91% stake in the company.

**5. Charles River Laboratories International (NYSE:CRL) Upgraded at Bank of America**
- Source: MarketBeat | 20251215T145504 | Bullish | Relevance: 100%
- Bank of America has upgraded Charles River Laboratories International (NYSE:CRL) from "neutral" to "buy," setting a $225 price objective that implies a 13.59% upside. This upgrade comes as the company continues to beat quarterly earnings estimates, with its stock currently trading near its 52-week high. Analysts collectively maintain a "Moderate Buy" consensus rating with a target price of $192.29, despite mixed individual price changes from other research firms.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 17.9x stretched relative to 7% growth. Analyst sentiment positive (2 raises, avg +9%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.6B |
| Beta | 1.64 |
| 52W Range | $91.86 - $200.58 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 17.9 |
| Current P/E | 19.1 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 8.0% to 9.7% (+1.7% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 95th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. AM_20 at 7.5% shows strong absolute momentum above own 20MA. Outperforming sector by 8.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.59), confirming momentum. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.73% (CS: 96) | Strong |
| RSI_14 | 67.0 | Neutral |
| MACD Histogram | 1.59 | Bullish |
| vs SMA20 | 1.075x | Above |
| vs SMA50 | 1.097x | Above |
| vs SMA200 | 1.248x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $195.99
- **Stop Loss:** $184.09 (6.1% risk)
- **Target:** $219.79 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $17,639.10
- **Portfolio %:** 17.64%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*